<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525796</url>
  </required_header>
  <id_info>
    <org_study_id>107407</org_study_id>
    <nct_id>NCT02525796</nct_id>
  </id_info>
  <brief_title>Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism</brief_title>
  <official_title>Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in&#xD;
      combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium&#xD;
      levels in primary hyperparathyroidism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To conduct a double-blinded, placebo-controlled, randomized intervention study to investigate&#xD;
      whether mineralocorticoid receptor (MR) antagonism, alone or in combination with cinacalcet,&#xD;
      is an effective therapy for primary hyperparathyroidism (P-HPTH).&#xD;
&#xD;
      Hypothesis: MR antagonism, as a monotherapy or in combination with a calcimimetic, is a&#xD;
      mechanism to lower parathyroid hormone (PTH) in primary hyperparathyroidism (P-HPTH).&#xD;
&#xD;
      Study Design: Sixty subjects with P-HPTH will be enrolled to randomly receive eplerenone (a&#xD;
      potassium-sparing diuretic that directly blocks the MR), amiloride (a potassium-sparing&#xD;
      diuretic that does not directly block the MR), or placebo for 4 weeks. Thereafter, all&#xD;
      subjects will receive cinacalcet therapy (a calcimimetic that lowers PTH) in addition to&#xD;
      their randomized intervention for an additional 2 weeks.&#xD;
&#xD;
      Anticipated Results: In this proof-of-concept study, eplerenone therapy will lower PTH, serum&#xD;
      calcium, and markers of bone resorption in P-HPTH, when compared to placebo. The PTH response&#xD;
      to amiloride will resemble that of placebo, suggesting that the eplerenone mediated&#xD;
      reductions in PTH are specific to interactions with the MR. Combination therapy with&#xD;
      eplerenone + cinacalcet will result in additive or synergistic reductions in PTH, when&#xD;
      compared to placebo + cinacalcet or placebo + amiloride.&#xD;
&#xD;
      Implications: MR antagonism (alone or in combination with cinacalcet) may be a mechanism to&#xD;
      lower PTH and calcium in P-HPTH, thereby identifying a new potential option in the limited&#xD;
      medical therapies for P-HPTH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in parathyroid hormone levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in circulating PTH levels before and after intervention when compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in calcium levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum calcium levels before and after intervention when compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Placebo + Cinacalcet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with primary hyperparathyroidism will receive placebo for 4 weeks followed by the addition of cinacalcet for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiloride + Cinacalcet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with primary hyperparathyroidism will receive amiloride for 4 weeks followed by the addition of cinacalcet for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone + Cinacalcet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with primary hyperparathyroidism will receive eplerenone for 4 weeks followed by the addition of cinacalcet for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eplerenone</intervention_name>
    <description>eplerenone, titrated up to a maximum of 50mg BID</description>
    <arm_group_label>Eplerenone + Cinacalcet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amiloride</intervention_name>
    <description>amiloride, titrated up to a maximum of 10mg BID</description>
    <arm_group_label>Amiloride + Cinacalcet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Cinacalcet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID</description>
    <arm_group_label>Amiloride + Cinacalcet</arm_group_label>
    <arm_group_label>Eplerenone + Cinacalcet</arm_group_label>
    <arm_group_label>Placebo + Cinacalcet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  physician diagnosis of active P-HPTH (Serum calcium &gt; upper limit of reference range&#xD;
             and serum PTH &gt; ULRR; or Serum Calcium &gt; ULRR AND serum PTH &gt; 30 pg/mL; or Serum&#xD;
             Calcium within 0.2 mg/dL of the ULRR and PTH&gt;ULRR).&#xD;
&#xD;
          -  negative pregnancy test in women aged 18-45&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  estimated glomerular filtration rate &lt; 60mL/min/1,73m2&#xD;
&#xD;
          -  serum potassium &gt; 5.0 mmol/L&#xD;
&#xD;
          -  age &lt;18 or &gt;80 years&#xD;
&#xD;
          -  diabetes that is not well controlled (HbA1c&gt;8%)\&#xD;
&#xD;
          -  liver failure&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  history of myocardial infarction or stroke&#xD;
&#xD;
          -  active use of lithium&#xD;
&#xD;
          -  active chronic inflammatory conditions (such as inflammatory bowel disease, rheumatoid&#xD;
             arthritis, sarcoidosis)&#xD;
&#xD;
          -  initiation within 3 months of bisphosphonates or cinacalcet&#xD;
&#xD;
          -  need for imminent parathyroidectomy (within the next 6-8 weeks) as determined by their&#xD;
             endocrinologist or surgeon&#xD;
&#xD;
          -  absolute serum calcium &gt;13.0 mg/dL&#xD;
&#xD;
          -  positive pregnancy test on any of the study visits for women ages 18-45.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Vaidya, MD MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anand Vaidya, MD MMSc</last_name>
    <phone>617-525-8285</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly Connors</last_name>
    <phone>617-732-5186</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Connors</last_name>
      <phone>617-732-5186</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Anand Vaidya</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Cinacalcet</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared with interested investigators upon request 1 year after the study is completed. Investigators may request IPD by contacting the PI and proposing a data analysis plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

